AbCellera Biologics (NASDAQ:ABCL) used its full-year 2025 business update call to emphasize that it has completed its ...
It is an honor and a privilege to lead such a talented and committed team as Arvinas enters a period where we anticipate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results